A Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine

From the Laboratory of Martin Moore, Ph.D., Pediatrics, Emory

Cliff Michaels, Licensing Associate
OTT Breakfast Club, May 13th, 2014
RSV

Virus infecting the lower respiratory tract

Big problem for infants & children!

- Leading cause of viral death in children
- 100% infected by age 2
- 100,000 – 150,000 hospitalizations

No Therapeutic Treatments, only supportive care
Preventing RSV

Prophylactic Treatment Synagis (Medimmune)
- Moderately effective mAb
- Requires repeated dosing
- DOES NOT PROVIDE PROLONGED IMMUNITY

Vaccines
- None approved
- High profile Merck failure
- Issues – Genetic Stability & Poor Immunogenicity

Unmet need – long-term protection
Emory Vaccine

Use new techniques & target different proteins

WT RSV

Emory Vaccine

Improved immunogenicity
Enhanced Immunogenicity

Better & Prolonged immune response
Value proposition

• High unmet need for RSV vaccine
• Highly desirable area to pharma & biotech
• Promising preliminary data

IP Status – PCT application filed

Commercialization – We are interested in exploring a startup opportunity

Next Steps – Stability & Challenge experiments
Thank you!